— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year
— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis
— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent
— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end
— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019
— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis
— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was
